SFSahar Mashayekhi Firouz

Sahar Mashayekhi Firouz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sahar Mashayekhi Firouz has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Functionality of immune cells in COVID-19 infection: development of cell-based therapeutics

    by Maryam Sayahinouri, Sahar Mashayekhi Firouz, Amin Ebrahimi Sadrabadi, Mina Masoudnia, Mahnaz Abdolahi, Fatemeh Jafarzadeh, Meshkat Nouripour, Sana Mirzazadeh, Nazanin Zangeneh, Arsalan Jalili, et al.

    Introduction: In late December 2019, a sudden severe respiratory illness of unknown origin was reported in China. In early January 2020, the cause of COVID-19 infection was announced a new coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Examination of the SARS-CoV-2 genome sequence revealed a close resemblance to the previously reported SARS-CoV and coronavirus Middle East respiratory syndrome (MERS-CoV). However, initial testing of drugs used against SARS-CoV and MERS-CoV has been ineffective in controlling SARS-CoV-2. One of the key strategies to fight the virus is to look at how the immune system works against the virus, which has led to a better understanding of the disease and the development of new therapies and vaccine designs. Methods: This review discussed the innate and acquired immune system responses and how immune cells function against the virus to shed light on the human body's defense strategies. Results: Although immune responses have been revealed critical to eradicating infections caused by coronaviruses, dysregulated immune responses can lead to immune pathologies thoroughly investigated. Also, the benefit of mesenchymal stem cells, NK cells, Treg cells, specific T cells, and platelet lysates have been submitted as promising solutions to prevent the effects of infection in patients with COVID-19. Conclusion: It has been concluded that none of the above has undoubtedly been approved for the treatment or prevention of COVID-19, but clinical trials are underway better to understand the efficacy and safety of these cellular therapies.


  • Potential anti-inflammatory effect of anti-HMGB1 in animal models of ICH by downregulating the TLR4 signaling pathway and regulating the inflammatory cytokines along with increasing HO1 and NRF2

    by Ji Xu, Sahar Mashayekhi Firouz, Mina Farrokhian, Shadi Ghoreishizadeh, Talar Ahmad Merza Mohamad, Amirabbas Rostami, Rozita Tamjididfar, Morteza Akbari, Navid Shomali, Reza Eghdam Zamiri, et al.